ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. The company intends to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect’s initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
Companies To Watch
XXII 1.39 +0.01 CKPT 10.25 +0.00 CPHR 2.9901 +0.0000 CFRX 1.40 -0.10 CRBP 6.45 -0.30 DMPI 2.20 -0.10 DVAX 5.70 +0.15 FBIO 3.95 +0.11 KERX 6.46 +0.04 MTNB 3.00 -0.03 MDGN 5.57 +0.17 MNOV 5.95 -0.10 MTFB 8.99 +0.59 PRQR 5.00 +0.05 STML 8.45 +0.10 SYN 0.6068 +0.0148 TGTX 12.05 +0.15 THLD 0.4693 +0.0093 TNXP 4.46 +0.11 VSTM 2.37 +0.00 ZIOP 6.29 -0.28 2017-05-26 16:01
- Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
- Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
- Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol